Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy

Changhua Zhuo¹, Mingang Ying¹, Ruirong Lin¹, Xianyi Wu¹, Shen Guan¹ and Chunkang Yang¹

¹Department of Gastrointestinal Surgical Oncology, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou 350014, China

Correspondence to: Chunkang Yang, email: chuck330@163.com

Keywords: gastric cancer, palliative resection, negative lymph node, survival analysis, prognostic factor

Received: February 22, 2017  Accepted: March 27, 2017  Published: April 26, 2017

ABSTRACT

Negative lymph node (NLN) count has been validated as a protective predictor in various cancers after radical resection. However, the prognostic value of NLN count in the setting of stage IV gastric cancer patients who have received palliative resection has not been investigated. Surveillance, Epidemiology, and End Results Program (SEER)-registered gastric cancer patients were used for analysis in this study. Kaplan-Meier survival curves and multivariate Cox proportional hazards model were used to assess the risk factors for patients’ survivals. The results showed that NLN count and N stage were independently prognostic factors in patients with stage IV gastric cancer after palliative surgery (P< 0.001). X-tile plots identified 2 and 11 as the optimal cutoff values to divide the patients into high, middle and low risk subsets in term of cause-specific survival (CSS). And NLN count was proved to be an independently prognostic factor in multivariate Cox analysis (P< 0.001). The risk score of NLN counts demonstrated that the plot of hazard ratios (HRs) for NLN counts sharply increased when the number of NLN counts decreased. Collectively, our present study revealed that NLN count was an independent prognostic predictor in stage IV gastric cancer after palliative resection. Standard lymph node dissection, such as D2 lymphadectomy maybe still necessary during palliative resection for patients with metastatic gastric cancer.

INTRODUCTION

Gastric cancer is one of the most common and deadliest malignancies globally, especially in eastern Asian [1, 2]. For patients with resectable gastric cancer, surgical resection is the only potentially curative therapeutic modality, and the lymph node (LN) status turns to be the strongest prognostic indicator for survival after gastrectomy [3, 4]. According to the current tumor-node-metastasis (TNM) staging system for gastric cancer of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) and Japanese Gastric Cancer Association (JGCA) guideline, a minimum of 15 dissected LNs should be collected from gastric cancer samples for accurate histological examination and proper N stage assessment [5-7]. The number of retrieved LN counts was also validated as predictor after radical resection [6, 8, 9].

The proportion of stage IV cancer increased significantly during the last two decades and comprised more than 40% of total cases [10, 11]. The prognosis of gastric cancer patients with distant metastases is poor, and the 5-year overall survival (OS) rate rarely exceeds 5% if received palliative chemotherapy only [12]. Half of the patients with advanced gastric carcinoma will develop severe tumor-related complications, such as bleeding, obstruction and perforation, for the rest of their lives. Palliative surgery was recommended in this situation [11-13].

With advances in medical technologies, surgical interventions for patients with distant metastases are gaining more attention, and it has scientifically proved to have survival benefit [14, 15]. Meta-analysis showed that gastric resections were associated with a 2.5-fold higher OS rate than conservative treatment [11]. However, the clinical importance of regional LN in stage IV gastric is not fully understood.

The concept of negative lymph node (NLN) has recently attracted attention as a prognostic factor in colon [16, 17], gastric [9, 18], esophageal [19], and cervical [20] cancer.
However, the correlation between NLN count and prognosis in patients with stage IV gastric cancer is not clear. Thus, the aim of this retrospective study was to explore the effect of NLN counts on the survival outcomes in patients with stage IV gastric cancer after palliative resection.

RESULTS

Patient characteristics

A total of 1,495 patients with stage IV gastric cancer underwent palliative resection were identified from Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2011. The flow chart of the study was depicted in Figure 1. Of all patients, 144 (9.63%) were confirmed with no primary lymph node metastases (pN0), while 1,351 (90.37%) with primary lymph node involved (pN+). A detailed description of the associations between N stage and clinicopathological characteristics were presented in Table 1. As anticipated, patients of advanced T stage, poor differentiation and mucinous /signet ring cell had higher percentage of lymph node involved (P< 0.05).

Identification of optimal cutoffs of NLN in term of patients’ survival

The 5-year cause-specific survival (CSS) was 11.0% in this study cohort. NLN count was first treated as continuous variable, and it was validated as prognostic factor by univariate Cox regression analysis (hazard ratio (HR) = 0.961, 95% confidence interval (CI): 0.952-0.970, P<0.001). Then, the X-tile program was utilized to divide the patients into high, middle and low risk subgroups with cutoff value of 2 and 11 in terms of 5-year CSS (Figure 2). The 5-year CSS rate for patients with 0-1, 2-10 and ≥11 were 3.2%, 10.8% and 24%, respectively (χ² = 77.318, P< 0.001). Specifically, there was an absolute 20.8% increase in 5-year CSS rate if ≥ 11 NLNs were retrieved compared with those who had 0-1 NLN.

Prognostic impact of NLN counts

The numbers of NLN counts and other clinicopathological parameters, including sex (P= 0.005), grade (P= 0.013), histological type (P= 0.017), T stage (P< 0.001), and N stage (P< 0.001), were statistically significant variables in univariate analysis. They were further investigated by multivariate Cox regression analysis. The results demonstrated that only T stage...
(T3, HR= 1.098, 95% CI: 0.941-1.281, T4, HR= 1.343, 95% CI: 1.143- 1.577, P= 0.001, T1-2 as reference), N stage (N1, HR= 1.285, 95% CI: 0.965-1.713, N2, HR= 1.558, 95% CI: 1.187-2.045, N3, HR= 1.775, 95% CI: 1.373-2.296, P< 0.001, N0 as reference), and NLN count (2-10, HR= 0.762, 95% CI: 0.660-0.880, ≥11, HR= 0.525, 95% CI: 0.437- 0.632, P<0.001, 0-1 as reference) were significantly correlated with 5-year CSS (Table 2).

The risk score of NLN counts

The risk score of NLN counts was also built using the linear combination of NLN counts with the estimated regression coefficients derived from abovementioned Cox regression analysis. It was studied as the weight to calculate the death risk score for each patient. Distribution of death and the survival status of the patients with stage IV gastric cancer was shown in Figure 3. It showed that the plot of HRs for NLN counts increased sharply when the number of NLN counts decreased.

**Further analysis of the prognostic value of NLN counts according to N stage**

Since the N stage was one of the most powerful prognostic factors in stage I-III gastric cancer, we further made subgroup survival analysis to investigate the protective effect of higher NLN counts on patients' 5-year CSS (Table 3). As it is shown, for pN0 patients, there was an absolute 46.3% increase in 5-year CSS when ≥11 NLNs were harvested compared to those who with 0-1 NLN (P < 0.030) (Figure 4A). For pN1 patients, although
there also an increase in 5-year CSS when NLN counts increased, the difference was not significant ($P= 0.186$) (Figure 4B). For pN2 patients, the 5-year CSS for patients with 0-1, 2-10, ≥11 stage were 2.7%, 8.6% and 26.0%, respectively ($P< 0.001$), the 5-year CSS was nearly ten-folds in patients with ≥11 NLNs retrieved higher than that of 0-1 NLN (Figure 4C). For pN3 patients, the protective effect of NLN counts was also noticeable, the 5-year CSS for patients with 0-1, 2-10, ≥11 stage were 1.1%, 6.3% and 7.9% (Figure 4D).

**DISCUSSION**

To the best of our knowledge, this is the first study to systematically evaluate the clinical significance of NLN counts in metastatic gastric cancer patients based on public available database. The results showed that increased NLNs count was an independently prognostic factor in stage IV gastric cancer after palliative resection. Also, the pathologic N stage is another predictor in stage IV gastric cancer. To be noted, the total LN number which was validated as a prognostic value in stage I-III gastric cancer patients lost its significance in this study.

The purpose of palliative gastrectomy is to relieve the symptoms associated with cancer, to prevent subsequent tumor complications, and to improve the quality of life of patients [13, 21, 22]. The palliative gastric resection is safe with low comorbidity and mortality. Results published after the mid-1990s revealed the mortality rates did not exceed 7% [11, 21]. In consideration of the surgical related complications, however, palliative resection was often done with limited LN dissection, such as D0 or D1 lymphadectomy. Up to one-third of patients with distant metastases undergo gastric resection without curative intent [23]. Considering the prognostic effect of N stage and NLN counts in surgical specimens revealed by the present study, accurate identification of positive lymph nodes and standard lymphadectomy should be considered essential for treatment.

In fact, the value of NLN counts was previously studied in patients with gastrointestinal carcinomas. But all patients in the published studies were received radical surgical resection [9, 17, 24]. Zhou et al. reported the clinical significance of primary tumor lymph node status in stage IV gastric cancer, they found lower positive lymph node ratio (LNR) was an independent predictor of longer survival in patients with gastric cancer after palliative resection [25], but they had not studied the value of NLN counts.

The protective effect of increased NLN retrieval in stage IV gastric cancer is very interesting. The tumor burden in distant metastases seems to be more serious than the tumor cells left in regional lymph node. However, it might be not the truth. The protective role of increased NLN count maybe related to cancer immunity. There were two kind of cancer immunity surrounding the tumor environment, namely antitumor immunity and immunological tolerance [26]. The latter one inclines to cause immune tolerance with the progress of the cancer development [27]. Resection of regional LNs might reset the immunological balance, resulting in an improvement of patients’ prognosis.

Although patients included in the present study under strictly selection, there were still some potential limitations. First, the SEER database lacks detailed therapy information. There has been great advance in palliative chemotherapy for gastric cancer nowadays. Patients received different and multi-sequential chemotherapy may cause the bias of this study. Second, the number of patients was not large enough. After

![Figure 2: Cutoff value for NLN counts calculated using the X-tile program](image-url)
Table 2: Univariate and multivariate survival analyses for evaluating the influence of the number of NLNs retrieved on CSS in stage IV gastric cancer

| Variables                  | 5-year CSS rate | Univariate analysis | Multivariate analysis |
|----------------------------|-----------------|---------------------|-----------------------|
|                            |                 | χ²       | P       | HR (95% CI) | P       |
| Sex                        |                 |          |         |             |         |
| Male                       | 15.9%           | 7.816   | 0.005   | Reference   | 0.157   |
| Female                     | 5.1%            |          |         | 1.098 (0.965-1.249) |         |
| Age                        |                 | 2.732   | 0.098   |             |         |
| ≤ 60                       | 13.7%           |          |         |             |         |
| > 60                       | 10.4%           |          |         |             |         |
| Race                       |                 | 0.998   | 0.607   |             |         |
| Caucasian                  | 12.1%           |          |         |             |         |
| Black                      | 14.6%           |          |         |             |         |
| Others                     | 9.1%            |          |         |             |         |
| Grade                      |                 | 8.734   | 0.013   |             | 0.344   |
| High/ Moderate             | 12.2%           |          |         | Reference   |         |
| Poor/ Anaplastic           | 11.2%           |          |         | 1.086 (0.924-1.276) | 0.319   |
| Unknown                    | 18.3%           |          |         | 0.888 (0.615-1.283) | 0.528   |
| Histological type          |                 | 8.155   | 0.017   |             | 0.582   |
| Adenocarcinoma             | 13.5%           |          |         | Reference   |         |
| Mucinous/ signet ring cell | 7.4%            |          |         | 1.040 (0.905-1.194) |         |
| Tumor size (cm)            |                 | 2.290   | 0.130   |             |         |
| < 5                        | 12%             |          |         |             |         |
| ≥ 5                        | 11.7%           |          |         |             |         |
| T Stage                    |                 | 29.484  | < 0.001 |             | 0.001   |
| T1-2                       | 18.3%           |          |         | Reference   |         |
| T3                         | 7.9%            |          |         | 1.098 (0.941-1.281) | 0.235   |
| T4                         | 6.0%            |          |         | 1.343 (1.143-1.577) | < 0.001 |
| N stage                    |                 | 57.607  | < 0.001 |             | < 0.001 |
| N0                         | 32.7%           |          |         | Reference   |         |
| N1                         | 18.6%           |          |         | 1.285 (0.965-1.713) | 0.087   |
| N2                         | 13.3%           |          |         | 1.558 (1.187-2.045) | 0.001   |
| N3                         | 4.6%            |          |         | 1.775 (1.373-2.296) | < 0.001 |
| LNs retrieved              |                 | 0.542   | 0.461   |             |         |
| < 15                       | 12.3%           |          |         |             |         |
| ≥ 15                       | 11.4%           |          |         |             |         |
| NLN counts                 |                 | 77.318  | < 0.001 |             | < 0.001 |
| 0-1                        | 3.2%            |          |         | Reference   |         |
| 2-10                       | 10.8%           |          |         | 0.762 (0.660-0.880) | < 0.001 |
| ≥ 11                       | 24.0%           |          |         | 0.525 (0.437-0.632) | < 0.001 |

Abbreviation: CSS: cause-specific survival; HR: hazard ratio; 95% CI: 95% confidence interval; T stage: tumor infiltration depth; N stage: lymph node status; LNs: lymph nodes; NLN: negative lymph node. Kaplan-Meier survival curves and Log-rank tests were used to identify the univariate risk factors. Cox regression model was used to perform multivariate analysis. P-value <0.05 was considered to be statistically significant.
stratification by N stage, there were limited numbers in each subgroup. This may weaken the statistical power. Third, since the absence of information of metastatic tumor burden and treatment on metastases, the exact survival benefit might be exaggerated due to possible simultaneous metastasectomy.

In conclusion, our present study revealed that lymph node status was still a strong prognostic predictor of survival for gastric cancer patients with palliative resection. NLN count was an independent risk factor in stage IV gastric cancer after palliative resection. Increased NLN retrieval can improve the patients’ 5-year CSS. Standard LN dissection, such as D2 lymphadectomy maybe still necessary during palliative resection for patients with metastatic gastric cancer.

Figure 3: The risk score of NLN counts. The risk score of negative lymph node (NLN) counts was built using the linear combination of NLN counts with the estimated regression coefficients. Distribution of death and survival status of the patients was shown. It showed that the plot of hazard ratios (HRs) for NLN counts increased sharply when the number of NLN counts decreased.
### Table 3: Univariate and multivariate analyses of NLN count on 5-year CSS based on different N stage

| Subgroups | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | NLN counts | 5-year CSS rate | $\chi^2$ | $P$ | HR (95% CI) | $P$ | $P$ |
| pN0       |            |                  |        |     |            |     |     |
| 0-1       | 0          |                 | 10.615 | 0.005 | Reference |     | 0.030 |
| 2-10      | 25.9%      |                 |        |     | 0.551 (0.277-1.096) | 0.089 |
| $\geq$11  | 46.3%      |                 |        |     | 0.371 (0.177-0.775) | 0.008 |
| pN1       |            |                  | 3.362  | 0.186 |           |     |     |
| 0-1       | 12.0%      |                 |        |     | Reference |     |     |
| 2-10      | 20.1%      |                 |        |     | 0.652 (0.473-0.898) | 0.009 |
| $\geq$11  | 22.7%      |                 |        |     | 0.407 (0.269-0.617) | <0.001 |
| pN2       |            |                  | 26.503 | <0.001 |           |     | <0.001 |
| 0-1       | 2.7%       |                 |        |     | Reference |     |     |
| 2-10      | 8.6%       |                 |        |     | 0.759 (0.630-0.914) | 0.004 |
| $\geq$11  | 26.0%      |                 |        |     | 0.566 (0.441-0.727) | <0.001 |
| pN3       |            |                  | 22.509 | <0.001 |           |     | <0.001 |
| 0-1       | 1.1%       |                 |        |     | Reference |     |     |
| 2-10      | 6.3%       |                 |        |     | 0.759 (0.630-0.914) | 0.004 |
| $\geq$11  | 7.9%       |                 |        |     | 0.566 (0.441-0.727) | <0.001 |

Abbreviation: N stage: lymph node status; NLN: negative lymph node; CSS: cause-specific survival; HR: hazard ratio; 95% CI: 95% confidence interval. Kaplan-Meier survival curves and Log-rank tests were used to identify the univariate risk factors. Cox regression model was used to perform multivariate analysis. Three subgroups were adjusted for age, race, and pathological grading. Histological type and T stage were treated as the covariates. $P$-value <0.05 was considered to be statistically significant.

**Figure 4: Clinical significance of NLN counts on patients’ survival stratified by N stage.** Subpopulation analysis of the prognostic value of negative lymph node (NLN) counts on patients’ survival according to N stage. For pN0 patients, $\chi^2=10.615$, $P=0.005$ (A) For pN1 stage, $\chi^2=3.362$, $P=0.186$ (B) For pN2 stage, $\chi^2=26.503$, $P<0.001$ (C) For pN3 stage, $\chi^2=22.509$, $P<0.001$ (D) It showed that the protective (more favorable) effect of higher NLN counts on patients’ 5-year cause-specific survival (CSS).
PATIENTS AND METHODS

Patient characteristics

The clinical data of stage IV gastric cancer patients receiving palliative resection from January 2004 to December 2011 in SEER-registered database were retrieved. The SEER Program of the National Cancer Institute (NCI) is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering 28 percent of the United States population [28, 29]. SEER*Stat Software Version 8.3.2 (NCI, USA) was used to download the database (https://seer.cancer.gov/seerstat/).

Only cases who fulfilled the following criteria were eligible for this study: (1) Years of diagnosis span from 2004 to 2011; (2) histological types were confined to adenocarcinoma, mucinous adenocarcinoma, and signet ring cell cancer; (3) gastric patients were confirmed with distant metastasis (M1); (4) patients received primary tumor resection; (5) with detailed information of tumor infiltration depth (T) stage, lymph node status (N) stage, and primary tumor size; (6) ages of patients studied were above 16; and (7) information on 5-year CSS and survival time was available. All patients were restaged according to UICC/AJCC TNM Stage system (7th edition).

Statistical analyses

The associations between N stage and clinicopathological features were analyzed using Chi-square test. Risk factors for survival outcomes were identified by Kaplan-Meier survival curves and Log-rank tests. Only variables that were significance in univariate analysis were included in the Cox multivariate regression model analysis. The X-tile program (http://www.tissuearray.org/rimmlab/) [30] which identified the cutoff with the minimum P values from log-rank $\chi^2$ statistics was used to divide patients into high, middle and low risk subsets, as previously described [31]. The primary endpoint of this study was 5-year CSS. Deaths attributed to gastric cancer were treated as events, while other reasons caused deaths or survivals were defined as censored events. All analyses were performed with survival package of R (Ver. 3.3.1) and SPSS (Ver. 22.0, IBM Corp., USA). Difference with $P$-value <0.05 was considered to be statistically significant.

Author contributions

CHZ and CKY conceived of and designed the study. MGY and RRL performed the analyses. CHZ, XYW, SG, and MGY prepared all figures and tables. CHZ and CKY wrote the main manuscript. All authors reviewed and approved the manuscript.

CONFLICTS OF INTEREST

The authors have no potential conflicts of interest to disclose.

FUNDING

The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER database. This study was partially supported by the National Clinical Key Specialty Construction Program of China, and by grants from the Medical Innovation Program of Fujian Province (No. 2015-CXB-6 to Changhua Zhuo).

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108.
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67:7–30.
3. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol. 2014; 20:1635–49.
4. Lin JX, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, Jun L, Chen QY, Lin M, Tu R. Evaluation of laparoscopic total gastrectomy for advanced gastric cancer: results of a comparison with laparoscopic distal gastrectomy. Surg Endosc. 2016; 30:1988–98.
5. Raugei S, Dionigi G, Ruspi L, Proserpio I, Galli F, Tirotta F, Frattini F, Rovera F, Boni L, Pinotti G, Dionigi R. Lymph node staging in gastric cancer: new criteria, old problems. Int J Surg. Int J Surg. 2013; 11 Suppl 1:S90–4.
6. He H, Shen Z, Wang X, Qin J, Sun Y, Qin X. Survival benefit of greater number of lymph nodes dissection for advanced node-negative gastric cancer patients following radical gastrectomy. Jpn J Clin Oncol. 2016; 46:63–70.
7. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017; 20:1–19.
8. Zheng WF, Ji TT, Lin Y, Li RZ. The prognostic value of lymph nodes count on survival of patients with node-negative gastric cancer. Oncotarget. 2016; 7:43680–88. doi: 10.18632/oncotarget.9845.
9. Shi RL, Chen Q, Ding JB, Yang Z, Pan G, Jiang D, Liu W. Increased number of negative lymph nodes is associated with improved survival outcome in node positive gastric cancer following radical gastrectomy. Oncotarget. 2016; 7:35084–91. doi: 10.18632/oncotarget.9041.
10. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Breminkmeijer SJ, Lips DJ, Vd WurffAA, Bosscha K, Coebergh JW. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a
population-based study in the Netherlands. Eur J Cancer. 2010; 46:1101–10.

11. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer: a systematic review and meta-analysis. Anticancer Res. 2014; 34:2079–85.

12. Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, Yang HK. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012; 19:1231–39.

13. Dittmar Y, Rauchfuss F, Goetz M, Jandt K, Scheuerlein H, Heise M, Settmacher U. Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature. Langenbecks Arch Surg. 2012; 397:745–53.

14. Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, Tanabe K, Suzuki T. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology. 2011; 78:343–352.

15. Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013; 119:1636–42.

16. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006; 24:3570–75.

17. Li Q, Zhuo C, Cai G, Li D, Liang L, Cai S. Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIB and IIIC rectal cancer treated with preoperative radiotherapy. Oncotarget. 2014; 5:12459–71. doi: 10.18632/oncotarget.2560.

18. Deng J, Liang H, Wang D, Sun D, Ding X, Pan Y, Liu X. Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes. Ann Surg Oncol. 2010; 17:1043–51.

19. Zhu Z, Chen H, Yu W, Fu X, Xiang J, Li H, Zhang Y, Sun M, Wei Q, Zhao W, Zhao K. Number of negative lymph nodes is associated with survival in thoracic esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Surg Oncol. 2014; 21:2857–63.

20. Chen Y, Zhang L, Tian J, Ren X, Hao Q. Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients. Cancer Cell Int. 2013; 13:6.

21. Kulig P, Sierzega M, Kowalczyk T, Kolodziejczyk P, Kulig J. Non-curative gastrectomy for metastatic gastric cancer: rationale and long-term outcome in multicenter settings. Eur J Surg Oncol. 2012; 38:490–6.

22. Hsu JT, Liao JA, Chuang HC, Chen TD, Chen TH, Kuo CJ, Lin CJ, Chou WC, Yeh TS, Jan YY. Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer. BMC Palliat Care. 2017; 16:19.

23. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17:309–18.

24. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol. 2010; 105:420–33.

25. Zhou R, Wu Z, Zhang J, Wang H, Su Y, Huang N, Shi M, Bin J, Liao Y, Liao W. Clinical significance of accurate identification of lymph node status in distant metastatic gastric cancer. Oncotarget. 2016; 7:1029–41. doi: 10.18632/oncotarget.6009.

26. Zhuo C, Xu Y, Ying M, Li Q, Huang L, Li D, Cai S, Li B. FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer. Immunol Res. 2015; 61:338–47.

27. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother. 2009; 58:1363–73.

28. Li Q, Gan L, Liang L, Li X, Cai S. The influence of marital status on stage at diagnosis and survival of patients with colorectal cancer. Oncotarget. 2015; 6:7339–47. doi: 10.18632/oncotarget.3129.

29. Li Q, Liang L, Gan L, Cai G, Li X, Cai S. Effect of Lymph Node Count on Pathological Stage III Rectal Cancer with Preoperative Radiotherapy. Sci Rep. 2015; 5:16990.

30. Tamayo P, Slattery ML, Winer EP, Watanabe N, Watanabe H, Kato T, Gown AM, Preusser M, Sauter G. X-Tile: a new bi-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10:7259–69.

31. Zhao C, Li Q, Wu Y, Li Y, Nie J, Li D, Peng J, Lian P, Li B, Cai G, Li X, Cai S. LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. Oncotarget. 2015; 6:23820–36. doi: 10.18632/oncotarget.4450.